Fresenius Medical Care fell short of analyst expectations in Q2 2025, reporting an operating profit of €476 million—below the anticipated €492 million—despite a 9% year-over-year increase. The dialysis giant faced headwinds from a severe flu season in the US, its core market, which led to higher mortality rates among patients and stagnant treatment volumes. While new patient inflows grew for the fifth consecutive month, losses from the outbreak overshadowed gains. The company revised its full-year US growth forecast from 0.5% to flat or marginally positive, pinning hopes on a new, more efficient dialysis machine set to launch later this year.
Cost-Cutting Offsets Weak Demand
Aggressive cost reductions saved €58 million in Q2, part of a broader €1.05 billion efficiency plan through 2027. Product sales, particularly dialysis equipment, drove margin improvements, with revenue rising 1% nominally to €4.8 billion. The stock initially plunged 7% post-announcement but recovered to a 0.5% loss by afternoon trading. Meanwhile, a subsidiary completed the sale of select lab assets to a US diagnostics firm, transferring services for 200,000 patients. Despite the setbacks, management reaffirmed its full-year earnings growth target of 10–20%.
Ad
Fresenius Medical Care Stock: Buy or Sell?! New Fresenius Medical Care Analysis from February 7 delivers the answer:
The latest Fresenius Medical Care figures speak for themselves: Urgent action needed for Fresenius Medical Care investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Fresenius Medical Care: Buy or sell? Read more here...
